



World Health
Organization

The Use of Visceral Leishmaniasis Rapid Diagnostic Tests



Special Programme for Research & Training
in Tropical Diseases (TDR) sponsored by
UNICEF/UNDP/World Bank/WHO



The Use of Visceral Leishmaniasis Rapid Diagnostic Tests



**World Health
Organization**



**Special Programme for Research & Training
in Tropical Diseases (TDR) sponsored by
UNICEF / UNDP / World Bank / WHO**

WHO Library Cataloguing-in-Publication Data

The use of visceral leishmaniasis rapid diagnostic tests.

1.Leishmaniasis, Visceral - diagnosis. 2.Leishmaniasis, Visceral - prevention and control. 3.Antibodies, Protozoan - analysis. 4.Reagent strips - diagnostic use. 5.Immunologic tests -utilization. 6.Sensitivity and specificity. I.World Health Organization. II.UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases.

ISBN 978 92 4 159735 7

(NLM classification: WC 715)

Copyright © World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases 2008

All rights reserved.

The use of content from this health information product for all non-commercial education, training and information purposes is encouraged, including translation, quotation and reproduction, in any medium, but the content must not be changed and full acknowledgement of the source must be clearly stated. A copy of any resulting product with such content should be sent to TDR, World Health Organization, Avenue Appia, 1211 Geneva 27, Switzerland. TDR is a World Health Organization (WHO) executed UNICEF/UNDP/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases.

This information product is not for sale. The use of any information or content whatsoever from it for publicity or advertising, or for any commercial or income-generating purpose, is strictly prohibited. No elements of this information product, in part or in whole, may be used to promote any specific individual, entity or product, in any manner whatsoever.

The designations employed and the presentation of material in this health information product, including maps and other illustrative materials, do not imply the expression of any opinion whatsoever on the part of WHO, including TDR, the authors or any parties cooperating in the production, concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delineation of frontiers and borders.

Mention or depiction of any specific product or commercial enterprise does not imply endorsement or recommendation by WHO, including TDR, the authors or any parties cooperating in the production, in preference to others of a similar nature not mentioned or depicted.

The views expressed in this health information product are those of the authors and do not necessarily reflect those of WHO, including TDR. WHO, including TDR, and the authors of this health information product make no warranties or representations regarding the content, presentation, appearance, completeness or accuracy in any medium and shall not be held liable for any damages whatsoever as a result of its use or application. WHO, including TDR, reserves the right to make updates and changes without notice and accepts no liability for any errors or omissions in this regard. Any alteration to the original content brought about by display or access through different media is not the responsibility of WHO, including TDR, or the authors. WHO, including TDR, and the authors accept no responsibility whatsoever for any inaccurate advice or information that is provided by sources reached via linkages or references to this health information product.

Printed in the Philippines.

Contents

Introduction	3
I. What is visceral leishmaniasis (VL) and why is it important?	4
II. How is VL diagnosed?	5
III. What is a VL Rapid Diagnostic Test (RDT)?	7
IV. How is the rK39 RDT performed?	8
V. How effective are RDTs in detecting VL?	10
VI. When is an RDT useful?	11
VII. How useful is the rK39 RDT in the VL control program?	12
VIII. What do RDT results mean and when do you treat?	13
IX. What should you consider when purchasing RDTs for VL?	15
X. How do you transport and store RDTs?	17
XI. How do you evaluate the quality of your testing program?	19
Further readings	20
Text Box 1. Points to consider for the optimization of RDT use	8
Text Box 2. Advantages and disadvantages of the rK39 test	10
Text Box 3. To whom the rK39 RDT should be applied	11
Text Box 4. rK39 test can be of great value to the VL control program	12
Text Box 5. Information to obtain from RDT manufacturers	16
Figure 1. Comparative sensitivity of microscopy using different clinical specimens	5
Figure 2. Direct Agglutination Test (DAT)	6
Figure 3. rK39 RDT	6
Figure 4. How is the rK39 RDT read?	9
Figure 5. When do you treat?	14

We would like to acknowledge the valuable contributions of many colleagues towards the development of this guide, in particular, K. Gidwani and B. Khanal who wrote the initial draft and others including: J. Alvar, M. Banerjee, F. Chappuis, P. Desjeux, S. El Safi, T. Laxmi, D. Mondal, M. Mbuchi, M. Mukhtar, B. Ostyn, S. Rijal, K. Ritmeijer, H. Schallig, S.N. Sharma, S. Sundar, M. Wasunna.


To request copies and address queries, please contact:

Dr Rosanna Peeling, WHO/TDR
E-mail: peelingr@who.int

Dr Jane Cunningham, WHO/TDR
Email: cunninghamj@who.int

Dr Marleen Boelaert, ITM
Email: mboelaert@itg.be





Introduction

A reliable diagnosis is critical in the management of visceral leishmaniasis (VL). Early case detection and treatment improve prognosis for the patient and can reduce transmission, especially in *Leishmania donovani* areas as there is no animal reservoir.

Rapid diagnostic tests (RDTs) for VL are amongst the most important innovations in the control of VL. These tests allow for patients to be diagnosed closer to their homes. The demand for RDTs was such that counterfeit products began circulating in the Indian subcontinent soon after they were adopted in the VL elimination initiative.

This user guide provides general information on RDTs for VL but is not a manual for patient management. We hope it will facilitate proper use of RDTs and improve the quality of VL care. Though it was developed with the Indian subcontinent in mind, this guide can, with some minor local adaptations, be useful in other settings.

I. What is visceral leishmaniasis (VL) and why is it important?

Visceral leishmaniasis (VL), also known as kala-azar, is an infection transmitted by sand flies and caused by parasites of the genus *Leishmania*. An estimated 500 000 people acquire this disease each year, 90% of whom live in India, Nepal, Bangladesh, Sudan and Brazil. VL is predominantly a disease of the poor living in remote communities with few health care facilities.

The disease is characterized by fever, weight loss, enlargement of the liver, spleen and lymph nodes and low blood cell counts, all of which are non-specific signs and not all of which are present in each individual case. A *Leishmania* infection does not always lead to clinical disease as asymptomatic infections outnumber the clinical cases.

Early and accurate laboratory diagnosis is essential before initiating treatment for several reasons:

- i) the clinical features of VL resemble those of several other diseases including malaria or other conditions (infectious and not-infectious).
- ii) effective drugs are available but they need to be administered for a minimum 3 weeks and are potentially toxic and expensive.
- iii) VL is usually fatal if not treated in a timely manner.
- iv) untreated cases are reservoirs of infection and therefore put the community at risk of ongoing transmission.



预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29385

